Margaret A. Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Margaret A. Park has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Charles E. Chalfant
Department of Biochemistry & Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298-0614, United States; Hunter Holmes McGuire Veterans Administration Medical Center, Richmond, VA 23249, United States; The Massey Cancer Center, Richmond, VA 23298, United States
3 shared publications Charles Chalfant
Virginia Commonwealth University
2 shared publications- Aileen Garcia-Vargas
Virginia Commonwealth University, Department of Biochemistry, Cell and Molecular Biology, Sanger Hall, 1101 E. Marshall St., Richmond VA, 23298, USA
1 shared publication Amanda E. Gentry
Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia 23298
1 shared publicationBrian P. Griffin
From the Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond Virginia 23298
1 shared publication- Kellie J. Archer
Division of Biostatistics College of Public Health, The Ohio State University Columbus Ohio USA
1 shared publication
Latest Publications
- 11 October 2020
- Published by Springer Nature
- p. 1-17
Fatty Acid Metabolism
- Open Access
- 1 October 2015
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 290 (42) , 25717-25727
The Alternative Splicing of Cytoplasmic Polyadenylation Element Binding Protein 2 Drives Anoikis Resistance and the Metastasis of Triple Negative Breast Cancer
- 1 October 2015
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 290 (42) , 25717-25727
Open AccessThe Alternative Splicing of Cytoplasmic Polyadenylation Element Binding Protein 2 Drives Anoikis Resistance and the Metastasis of Triple Negative Breast Cancer
- 11 November 2013
- Vol. 1 (1) , 3-7
Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer
While the 5-year survival rate of breast cancer is at an all-time high of 90%, this disease remains the second most common cause of cancer-related death, surpassed only by lung cancer in the US. The reasons for this discrepancy stem from cancer subtypes which become resistant to current therapies. These subtypes: “Triple negative” and ErbB2-overexpressing, are discussed in this review.
- 11 November 2013
- Vol. 1 (1) , 3-7
Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer
While the 5-year survival rate of breast cancer is at an all-time high of 90%, this disease remains the second most common cause of cancer-related death, surpassed only by lung cancer in the US. The reasons for this discrepancy stem from cancer subtypes which become resistant to current therapies. These subtypes: “Triple negative” and ErbB2-overexpressing, are discussed in this review.
- Open Access
- 24 May 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 1-256
OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2
Background: Lapatinib is characterized as an ErbB1/ErbB2 dual inhibitor and has recently been approved for the treatment of metastatic breast cancer. In this study, we examined mechanisms associated with enhancing the activity of lapatinib via combination with other therapies. Methods: In the present studies, estrogen receptor (ER) positive and ER negative breast cancer cells were genetically manipulated to up- or downregulate eIF2-alpha, its phospho-mutant, Nck1, or Nck2, then treated with OSU-03012, lapatinib or the combination and assayed for cytotoxicity/cytostaticity using clonogenic assays. Results: Treatment of breast cancer cell lines with lapatinib and OSU-03012 (a small molecule derivative of the Cox-2 inhibitor celecoxib) induced synergistic cytotoxic/cytostatic effects. This combination therapy corresponded to an increase in the phosphorylation of eIF2-α at serine51 and a decrease in Nck1 expression. Ectopic expression of phospho-mutant eIF2-α (Ser51Ala) or downregulation of eIF2-α in addition to downregulation of the eIF2-α kinase PERK inhibited the synergistic and cytotoxic effects. Furthermore, ectopic expression of Nck1, but not Nck2 abolished the decrease in cell viability observed in combination-treated cells. Downregulation of Nck1 failed to “rescue” the ablation of the cytotoxic/cytostatic effects by the phospho-mutant of eIF2-α (Ser51Ala) demonstrating that Nck1 downregulation is upstream of eIF2-α phosphorylation in the anti-survival pathway activated by lapatinib and OSU-03012 treatment. Finally, co-immunoprecipitation assays indicated that eIF2-α dissociates from the Nck1/PP1 complex after OSU-03012 and lapatinib co-treatment. Conclusions: These data indicate that OSU-03012 and lapatinib co-treatment is an effective combination therapy, which functions to enhance cell killing through the Nck1/eIF2 complex. Hence, this complex is a novel target for the treatment of metastatic breast cancer.
- 24 May 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 1-256
Open AccessOSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2
Background: Lapatinib is characterized as an ErbB1/ErbB2 dual inhibitor and has recently been approved for the treatment of metastatic breast cancer. In this study, we examined mechanisms associated with enhancing the activity of lapatinib via combination with other therapies. Methods: In the present studies, estrogen receptor (ER) positive and ER negative breast cancer cells were genetically manipulated to up- or downregulate eIF2-alpha, its phospho-mutant, Nck1, or Nck2, then treated with OSU-03012, lapatinib or the combination and assayed for cytotoxicity/cytostaticity using clonogenic assays. Results: Treatment of breast cancer cell lines with lapatinib and OSU-03012 (a small molecule derivative of the Cox-2 inhibitor celecoxib) induced synergistic cytotoxic/cytostatic effects. This combination therapy corresponded to an increase in the phosphorylation of eIF2-α at serine51 and a decrease in Nck1 expression. Ectopic expression of phospho-mutant eIF2-α (Ser51Ala) or downregulation of eIF2-α in addition to downregulation of the eIF2-α kinase PERK inhibited the synergistic and cytotoxic effects. Furthermore, ectopic expression of Nck1, but not Nck2 abolished the decrease in cell viability observed in combination-treated cells. Downregulation of Nck1 failed to “rescue” the ablation of the cytotoxic/cytostatic effects by the phospho-mutant of eIF2-α (Ser51Ala) demonstrating that Nck1 downregulation is upstream of eIF2-α phosphorylation in the anti-survival pathway activated by lapatinib and OSU-03012 treatment. Finally, co-immunoprecipitation assays indicated that eIF2-α dissociates from the Nck1/PP1 complex after OSU-03012 and lapatinib co-treatment. Conclusions: These data indicate that OSU-03012 and lapatinib co-treatment is an effective combination therapy, which functions to enhance cell killing through the Nck1/eIF2 complex. Hence, this complex is a novel target for the treatment of metastatic breast cancer.
- 15 June 2009
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 8 (12) , 1122-1124
The relationship between multidrug resistance and glucosylceramide levels: An opportunity for combined therapies
- 15 June 2009
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 8 (12) , 1122-1124
The relationship between multidrug resistance and glucosylceramide levels: An opportunity for combined therapies